Davuluri S, Duvuri B, Lood C, Faghihi-Kashani S, Chung L. Calcinosis in dermatomyositis: Origins and possible therapeutic avenues. Best Pract Res Clin Rheumatol. 2022;36: 101768. https://doi.org/10.1016/j.berh.2022.101768.

Article  PubMed  PubMed Central  Google Scholar 

Lundberg I, Fujimoto M, Vencovsky J, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021;7:86. https://doi.org/10.1038/s41572-021-00321-x.

Article  PubMed  Google Scholar 

• McCann LJ, Juggins AD, Maillard SM, et al. The Juvenile Dermatomyositis National Registry and 290 Repository (UK and Ireland) - clinical characteristics of children recruited within the first 5 yr. Rheumatology. 2006;45:1255–60. https://doi.org/10.1093/rheumatology/kel099. This study describes a cohort that helps understand the natural history of the disease.

Article  CAS  PubMed  Google Scholar 

Clemente G, Piotto DGP, Barbosa C, et al. High frequency of calcinosis in juvenile 293 dermatomyositis: a risk factor study. Rev Bras Reumatol. 2012;52:549–53.

Article  PubMed  Google Scholar 

Chander S, Gordon P. Soft tissue and subcutaneous calcification in connective tissue diseases. Curr Opin Rheumatol. 2012;24:158–64. https://doi.org/10.1097/BOR.0b013e32834ff5cd.

Article  CAS  PubMed  Google Scholar 

Chung MP, Richardson C, Kirakossian D, et al. Calcinosis biomarkers in adult and juvenile dermatomyositis. Autoimmun Rev. 2020;19: 102533. https://doi.org/10.1016/j.autrev.2020.102533.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Elahmar H, Feldman BM, Johnson SR. Management of calcinosis cutis in rheumatic diseases. J Rheumatol. 2022;49:980–9. https://doi.org/10.3899/jrheum.211393.

Article  CAS  PubMed  Google Scholar 

Shinjo SK, Souza FH. Update on the treatment of calcinosis in dermatomyositis. Rev Bras Reumatol. 2013;53:211–4.

PubMed  Google Scholar 

Traineua H, Aggarwal R, Monfort J-B, et al. Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature. J Am Acad Dermatol. 2022;82:317–25. https://doi.org/10.1016/j.jaad.2019.07.006.

Article  CAS  Google Scholar 

Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344–7. https://doi.org/10.1056/NEJM197502132920706.

Article  CAS  PubMed  Google Scholar 

•• Duvvuri B, Pachman LM, Hermanson P, et al. Role of mitochondria in the myopathy of juvenile dermatomyositis and implications for skeletal muscle calcinosis. J Autoimmun. 2023;138: 103061. https://doi.org/10.1016/j.jaut.2023.103061. This study highlights possible pathophysiological pathways of calcinosis in JDM.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mastrolia MV, Orsini SI, Marrani E, et al. Efficacy of Janus kinase inhibitor baricitinib in the treatment of refractory juvenile dermatomyositis complicated by calcinosis. Clin Exp Rheumatol. 2023;41:402–3. https://doi.org/10.55563/clinexprheumatol/7k9ajj.

Article  PubMed  Google Scholar 

• Sener S, Basaran O, Batu ED, et al. Early-onset juvenile dermatomyositis: A tertiary referral center experience and review of the literature. Semin Arthritis Rheum. 2023;58: 152133. https://doi.org/10.1016/j.semarthrit.2022.152133. This study describes a cohort that helps understand the natural history of the disease.

Article  PubMed  Google Scholar 

• Cancarini P, Nozawa T, Whitney K, et al. The clinical features of juvenile dermatomyositis: A single-centre inception cohort. Semin Arthritis Rheum. 2022;57: 152104. https://doi.org/10.1016/j.semarthrit.2022.152104. This study describes a cohort that helps understand the natural history of the disease.

Article  CAS  PubMed  Google Scholar 

• El-Garf K, El-Garf A, Salah S, Marzouk H, Farag Y, Mostafa N. A juvenile dermatomyositis: demographics, characteristics and disease outcome in an Egyptian cohort. Clin Exp Rheumatol. 2022;40:450–6. https://doi.org/10.55563/clinexprheumatol/h0s7tq. This study describes a cohort that helps understand the epidemiology of the disease.

Article  PubMed  Google Scholar 

Janarthanan M, Mohan M, Murali A. Bisphosphonate therapy for juvenile dermatomyositis-associated calcinosis and metaphyseal zebra lines. BMJ Case Rep. 2022;15: e252814. https://doi.org/10.1136/bcr-2022-252814.

Article  PubMed  Google Scholar 

Jin J, Yu H. Use of adalimumab in a child with juvenile dermatomyositis and calcinosis. Indian J Pediatr. 2022;89:1270. https://doi.org/10.1007/s12098-022-04332-8.

Article  PubMed  Google Scholar 

Linan-Barroso JM, Gonzalez-Estrada A, García-Morillo JS. Therapy-resistant dermatomyositis with extensive ‘lumbar belt’ calcinosis. BMJ Case Rep. 2022;15: e249110. https://doi.org/10.1136/bcr-2022-249110.

Article  PubMed  Google Scholar 

Neely J, Long CS, Sturrock H, Kim S. Association of short-term ultraviolet radiation exposure and disease severity in juvenile dermatomyositis: results from the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry. Arthritis Care Res (Hoboken). 2019;71:1600–5. https://doi.org/10.1002/acr.23840.

Article  PubMed  Google Scholar 

Nitiyarom R, Charuvanji S, Likasitwattanakul S, et al. Juvenile dermatomyositis in Thai children: Retrospective review of 30 cases from a tertiary care center. Indian J Dermatol Venereol Leprol. 2023;88:162–70. https://doi.org/10.25259/IJDVL_297_20.

Article  Google Scholar 

Toplak N, Pimpale Chavan P, et al. Is Anti-NXP2 autoantibody a risk factor for calcinosis and poor outcome in juvenile dermatomyositis patients? Case Series Front Pediatr. 2022;9: 810785. https://doi.org/10.3389/fped.2021.810785.

Article  PubMed  Google Scholar 

Concannon A, Han DY. Incidence, severity and clinical manifestations of juvenile dermatomyositis among Maori and Pacific Island compared to European children. J Paediatr Child Health. 2021;57:1881–5. https://doi.org/10.1111/jpc.15595.

Article  PubMed  Google Scholar 

Chung CH. Calcinosis universalis in juvenile dermatomyositis. Chonnam Med J. 2020;56: 212213. https://doi.org/10.4068/cmj.2020.56.3.212.

Article  Google Scholar 

• Campanilho-Marques R, Deakin CT, Simou S, et al. Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients. Arthritis Res Ther. 2020;22:79. https://doi.org/10.1186/s13075-020-02164-5. This study describes a cohort that helps understand the disease's response to immunobiologicals.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giri S, Parida JR, Dash M, Panda M. pamidronate in treatment of calcinosis in juvenile dermatomyositis. Indian Pediatr. 2020;57:75–6.

Article  PubMed  Google Scholar 

Lebrón CV, Montesino MDR, Navarrete VM, Miera FJTS. Treatment with rituximab in juvenile dermatomyositis: effect on calcinosis. Reumatol Clin. 2020;16:368–70. https://doi.org/10.1016/j.reuma.2018.06.010.

Article  Google Scholar 

Moegle C, Lipsker D. Juvenile dermatomyositis: A series of 22 cases. Ann Dermatol Venereol. 2020;147:494–503. https://doi.org/10.1016/j.annder.2020.04.016.

Article  CAS  PubMed  Google Scholar 

Tsaltskan V, Aldous A, Serafi S, et al. Long-term outcomes in juvenile myositis patients. Semin Arthritis Rheum. 2020;50:149–55. https://doi.org/10.1016/j.semarthrit.2019.06.014.

Article  PubMed  Google Scholar 

Rathore U, Gupta L. Scalp calcinosis in juvenile dermatomyositis. Rheumatology. 2020;60:1569. https://doi.org/10.1093/rheumatology/keaa566.

Article  Google Scholar 

Sukumaran S, Vijayan V. Abatacept in the treatment of juvenile dermatomyositis-associated calcifications in a 16-year-old girl. Case Rep Rheumatol. 2020;28:4073879. https://doi.org/10.1155/2020/4073879.

Article  Google Scholar 

Li J, Zhou Z. Calcinosis in juvenile dermatomyositis. N Engl J Med. 2019;381: e31. https://doi.org/10.1056/nejmicm1809669.

Article  PubMed  Google Scholar 

Gupta P, Shruti S, Chaudhary V, Khullar G, Siraj F. Juvenile dermatomyositis: A case report and review of literature. Cureus. 2019;11: e3935. https://doi.org/10.7759/cureus.3935.

Article  PubMed  PubMed Central  Google Scholar 

Çakan M, Karadağ ŞG, Ayaz NA. Complete and sustained resolution of calcinosis universalis in a juvenile dermatomyositis case with mycophenolate mofetil. Turk J Pediatr. 2019;61:771–5. https://doi.org/10.24953/turkjped.2019.05.018.

Article  PubMed  Google Scholar 

• Orandi AB, Dharnidharka VR, Al-Hammadi N, et al. Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis. Pediatr Rheumatol Online J. 2018;16:84. https://doi.org/10.1186/s12969-018-0299-9. This study helps understand the disease's response to immunobiologicals.

Al-Mayouf SM, Al Mutiari N, Muzaffer M, et al. Phenotypic characteristics and outcome of juvenile dermatomyositis in Arab children. Rheumatol Int. 2017;37:1513–7. https://doi.org/10.1007/s00296-017-3770-x.

Article  PubMed  Google Scholar 

Barut K, Ydin POA, Adrovic A, Sahin S, Kasapcopur O. Juvenile dermatomyositis: a tertiary center experience. Clin Rheumatol. 2017;36:361–6. https://doi.org/10.1007/s10067-016-3530-4.

Article  PubMed  Google Scholar 

Grijsen ML, Mchaile D, Geult I, et al. Juvenile dermatomyositis in a 4-year-old Kenyan girl. Clin Case Rep. 2017;5:134–8. https://doi.org/10.1002/ccr3.816.

Article  PubMed  PubMed Central  Google Scholar 

Phillippi K, Hoeltzel M, Byun Robinson A, et al. Race, income, and disease outcomes in juvenile dermatomyositis. J Pediatr. 2017;184(38–44): e1. https://doi.org/10.1016/j.jpeds.2017.01.046.

Article